Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.

Antimicrobial Agents and Chemotherapy
Ze-Ming WangA-Dong Shen

Abstract

Data of developmental pharmacokinetics (PK) of meropenem in critically ill infants and children with severe infections are limited. We assessed the population PK and defined the appropriate regimen to optimize treatment in this population based on developmental PK-pharmacodynamic (PD) analysis. Blood samples were collected from pediatric intensive care unit patients with severe infection treated with standard dosage regimens for meropenem. Population PK data were analyzed using NONMEM software. Fifty-seven patients (mean age, 2.96 years [range, 0.101 to 14.4]; mean body weight, 15.8 kg [range, 5.0 to 65.0]) were included. A total of 135 meropenem concentrations were obtainable for population PK modeling. The median number of samples per patients was 2 (range, 1 to 4). A two-compartment model with first-order elimination was optimal for PK modeling. Weight and creatinine clearance (estimated by the Schwartz formula) were significantly correlated with the PK parameters of meropenem. The probabilities of target attainment for pathogens with low MICs of 1 and 2 μg/ml were 87.5% and 68.6% following administration of 40 mg/kg/dose (every 8 h [q8h]) as a 4-h infusion and 98.0% and 73.3% with high MICs of 4 and 8 μg/ml following admini...Continue Reading

References

Dec 16, 2004·The Annals of Pharmacotherapy·Robert E ArianoSheryl A Zelenitsky
Jan 7, 2006·Journal of Clinical Pharmacology·Xiaoli DuDavid P Nicolau
Jul 7, 2007·Pharmaceutical Research·Andrew C HookerMats O Karlsson
Jan 25, 2008·Computer Methods and Programs in Biomedicine·Emmanuelle CometsFrance Mentré
Jul 16, 2008·International Journal of Antimicrobial Agents·Francesco Scaglione, Luca Paraboni
Jan 23, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuro IkawaMasao Kobayashi
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Mar 9, 2011·Therapeutic Drug Monitoring·A Franciscus van der MeerCees Neef
Sep 2, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S BradleyUNKNOWN Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
Apr 7, 2016·European Journal of Clinical Pharmacology·Francesca MattioliAntonello Di Paolo
Jun 28, 2016·International Journal of Antimicrobial Agents·Kritsana KongthavonsakulPeninnah Oberdorfer
Dec 10, 2016·SpringerPlus·Zhihui HeLi Jiang
Sep 26, 2017·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Jeffrey J CiesArun Chopra
Jan 31, 2018·Antimicrobial Agents and Chemotherapy·Zhong-Ren ShiWei Zhao
Feb 13, 2018·American Journal of Infection Control·John Rene LabibBasant Meligy
Feb 14, 2018·Antimicrobial Agents and Chemotherapy·Xing-Kai ChenWei Zhao
Oct 26, 2018·Anaesthesia Critical Care & Pain Medicine·Janattul-Ain JamalJason A Roberts
Nov 7, 2019·Clinical and Translational Science·Hazem E HassanThomas P Green

❮ Previous
Next ❯

Citations

Feb 12, 2021·Clinical Pharmacology and Therapeutics·Cornelia B Landersdorfer, Roger L Nation
Jun 23, 2021·Clinical Pharmacokinetics·Samit GangulyUNKNOWN Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
Aug 23, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Wanlika YonwisesWanchai Treyaprasert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Enfermedades infecciosas y microbiología clínica
Antibiotiki i khimioterapii︠a︡ = Antibiotics and chemoterapy [sic]
S M Shatunov, Iu B Belousov
The Pediatric Infectious Disease Journal
J S Bradley
© 2022 Meta ULC. All rights reserved